Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lodrane 24D** is an extended-release combination pharmaceutical product containing **brompheniramine maleate** (12 mg), an antihistamine, and **pseudoephedrine sulfate** (or HCl), a nasal decongestant, formulated for once-daily dosing. It provides symptomatic relief from nasal congestion, runny nose, sneezing, itchy/watery eyes, and other upper respiratory symptoms associated with **allergic rhinitis**, **common cold**, **hay fever**, **seasonal/perennial allergies**, **vasomotor rhinitis**, and related conditions like sinusitis or flu. Brompheniramine blocks histamine H1 receptors to reduce allergic responses, while pseudoephedrine acts as an alpha-adrenergic agonist to vasoconstrict nasal blood vessels and decrease congestion. Developed using Elite Pharmaceuticals' controlled-release technology (e.g., bead systems for sustained delivery over 24 hours), it was launched around 2006 via partnerships like ECR Pharmaceuticals (Hi-Tech Pharmacal subsidiary) and is available as prescription/OTC capsules.[1][3][6][7][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lodrane 24D.